Russia’s Sputnik V COVID-19 vaccine shows 91.6% efficacy in late-stage trial By: MarketWatch February 02, 2021 at 12:13 PM EST Preliminary findings, published in The Lancet on Tuesday, are based on data gathered from 19,866 participants. Read More >> Related Stocks: Astrazeneca Plc ADR Biontech Se ADR Johnson & Johnson Moderna Inc Pfizer